1.Survival after surgery for acute type A aortic dissection in octogenarians.
Antonio FIORE ; Javier Rodriguez LEGA ; Joscha BUECH ; Giovanni MARISCALCO ; Andrea PERROTTI ; Konrad WISNIEWSKI ; Angel G PINTO ; Till DEMAL ; Jan ROCEK ; Petr KACER ; Giuseppe GATTI ; Igor VENDRAMIN ; Mauro RINALDI ; Eduard QUINTANA ; Dario Di PERNA ; Francesco NAPPI ; Mark FIELD ; Amer HARKY ; Matteo PETTINARI ; Angelo M DELL'AQUILA ; Francesco ONORATI ; Mikko JORMALAINEN ; Tatu JUVONEN ; Timo MÄKIKALLIO ; Caroline RADNER ; Sven PETERSS ; Vito D'ANDREA ; Fausto BIANCARI
Journal of Geriatric Cardiology 2024;21(11):1015-1025
OBJECTIVE:
To evaluate the benefits of surgical repair acute type A aortic dissection (ATAAD) on survival of octogenarians.
METHODS:
Patients who underwent surgery for acute ATAAD from the multicenter European Registry of Type A Aortic Dissection (ERTAAD) were the subjects of the present analysis.
RESULTS:
326 (8.4%) patients were aged ≥ 80 years. Among 280 propensity score matched pairs, in-hospital mortality was 30.0% in patients aged ≥ 80 years and 20.0% in younger patients (P = 0.006), while 10-year mortality were 93.2% and 48.0%, respectively (P < 0.001). The hazard of mortality was higher among octogenarians up to two years after surgery, but it became comparable to that of younger patients up to 5 years. Among patients who survived 3 months after surgery, 10-year relative survival was 0.77 in patients aged < 80 years, and 0.46 in patients aged ≥ 80 years. Relative survival of octogenarians decreased markedly 5 years after surgery. Age ≥ 85 years, glomerular filtration rate, preoperative invasive ventilation, preoperative mesenteric mal-perfusion and aortic root replacement were independent predictors of in-hospital mortality among octogenarians (AUC = 0.792; E:O ratio = 0.991; CITL = 0.016; slope = 1.096). An additive score was developed. A risk score ≤ 1 was observed in 68.4% of patients, and their in-hospital mortality was 20.9%.
CONCLUSIONS
Provided a thoughtful patient selection, surgery may provide a survival benefit in patients aged ≥ 80 years with ATAAD that, when compared to younger patients and the general population, may last up to 5 years after the procedure. These findings have significant epidemiologic and clinical relevance because of the increasing longevity of the population of the Western countries.
2.Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab.
Andrea TENDAS ; Pasquale NISCOLA ; Laura SCARAMUCCI ; Luca CUPELLI ; Alessio Pio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2016;51(2):137-138
No abstract available.
Red-Cell Aplasia, Pure*
;
Rituximab*
3.Pure erythroid leukemia in advanced breast cancer.
Pasquale NISCOLA ; Andrea TENDAS ; Mauro MINELLI ; Alessio PERROTTI ; Paolo DE FABRITIIS ; Giovanni DEL POETA
Blood Research 2014;49(1):69-72
No abstract available.
Breast Neoplasms*
;
Breast*
;
Leukemia*
4.Long-term survival of a patient with bone marrow gelatinous degeneration of idiopathic origin.
Pasquale NISCOLA ; Massimiliano PALOMBI ; Stefano FRATONI ; Malgorzata Monika TRAWINSKA ; Laura SCARAMUCCI ; Andrea TENDAS ; Marco GIOVANNINI ; Alessio PERROTTI ; Paolo DE FABRITIIS
Korean Journal of Hematology 2012;47(4):309-310
No abstract available.
Bone Marrow
;
Gelatin
;
Humans

Result Analysis
Print
Save
E-mail